1 months vs 11 2 months, P = 0 0149) However, other factors suc

1 months vs. 11.2 months, P = 0.0149). However, other factors such as gender and smoking status have no obvious correlation to OS. In addition, we found that the OS of patients with rash was longer than that of patients without rash, and a longer OS was coupled with greater rash. Because there were few cases with grade 2 or more serious rash, this result needs to be verified SC79 molecular weight further. Moreover, our study showed favorable efficacy of gefitinib in patients with brain metastasis. Gefitinib is well tolerated in advanced NSCLC. The common adverse effects of gefitinib were skin rash, diarrhea, anorexia, elevated

aminotransferase lever, and interstitial lung disease, etc [9–11, 19]. Similarly, mild toxicities PF-6463922 research buy including skin rash (53.3%), diarrhea (33%), Grade 2 or 3 hepatic toxicity (6.7%), and oral ulcer (4.4%) were observed in our study. No patients developed ILD. Since the tolerance of gefitinib in NSCLC is better than chemotherapy, and gefitinib could provide clinical benefits for patients with extremely poor PS [11,

12], it may be a better choice to treat patients who can’t tolerate chemotherapy compared to best supportive care (BSC). It has been recently reported that the sensitivity and survival benefit of gefitinib MK-4827 supplier treatment was higher in NSCLC patients with EGFR mutations than the patients without EGFR mutations [20–22]. Chinese patients of lung cancer have a higher frequency of EGFR mutations than American patients. As a result, Chinese patients were much more sensitive to gefitinib than Americans [23]. Besides mutations, gene copy number and polymorphism of EGFR were also related to the responsiveness of gefitinib in advanced NSCLC [24, 25]. EGFR mutations of NSCLC patients can be detected using plasma and pleural effusion samples, which provides a noinvasive method to predict the efficacy of gefitinib in advanced NSCLC [26]. Detecting the mutations of EGFR plays an important role in guiding the first-line treatment with gefitinib in patients with advanced NSCLC. Besides

EGFR mutations, the favorable PFS after clonidine gefitinib treatment was also associated with high levels of serum surfactant protein D (SP-D) [27]. In future studies, we will investigate the molecules which affect and (or) can be used to predict the efficacy of gefitinib in NSCLC. Conclusions Single agent treatment with gefitinib is effective in patients with advanced NSCLC, and well tolerated in Chinese patients. Gefitinib could be used as first-line treatment for specific subgroups of NSCLC such as females, non-smokers, and patients with adenocarcinoma. Acknowledgements This work was supported by grants from the Jiangsu Provincial Natural Science Foundation (NO. BK2008477), the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry 2009 (IA09), and the open project program of the Health Bureau of Jiangsu province (XK18 200904). References 1.

Comments are closed.